TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39012

Group type: EXPERIMENTAL
Intervention: Prazepam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorazepate dipotassium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All drug groups
Number of subjects: 60
Study: 30799269

Group type: EXPERIMENTAL
Intervention: LIA with LB 266 mg/20 mL admixed with bupivacaine HCl 0.5% 20 mL
Number of subjects: 139
Study: 28953735

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day
Number of subjects: 94
Study: 25849298

Group type: EXPERIMENTAL
Intervention: ENB‐TBNA
Number of subjects: 94

Group type: COMPARATOR
Intervention: C‐TBNA
Number of subjects: 94
Study: 23422155

Group type: EXPERIMENTAL
Intervention: Ulinastatin (10,000 units/kg intravenously before surgical incision and 5,000 units/kg on post-op days 1-3)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no ulinastatin)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 20823079

Group type: EXPERIMENTAL
Intervention: Scopolamine bromide (0.4 mg i.m.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study: 19940321

Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking program (MI-WP)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Low-intensity activity program (LI-AP)
Number of subjects: 152
Study: 17388713

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/day increased to 20 mg/day after week 4)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (after tapering from escitalopram)
Number of subjects: 24
Study: 14696230

Group type: EXPERIMENTAL
Intervention: OptiMARK (gadoversetamide injection) administered via power injector
Number of subjects: 144
Study: 11177120

Group type: EXPERIMENTAL
Intervention: Organized depression management program including patient education, antidepressant pharmacotherapy, systematic telephone monitoring, and psychiatric consultation.
Number of subjects: 407

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Total health services costs (including health services and time-in-treatment costs).
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Outpatient health services costs.
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Health services plus time-in-treatment costs.
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Total health services and time-in-treatment costs.
Number of subjects: 407
Study: 9717065

Group type: EXPERIMENTAL
Intervention: Bezafibrate retard (400 mg once daily)
Number of subjects: 3122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3122
Study: 8169394

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg) single dose
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg) two consecutive days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Thiabendazole (50 mg/kg/day) twice daily for 3 consecutive days
Number of subjects: 53
Study: 3168573

Group type: EXPERIMENTAL
Intervention: Metaproterenol, 5 percent solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Isoetharine, 1 percent solution
Number of subjects: 6

Group type: COMPARATOR
Intervention: Atropine (control)
Number of subjects: 6
Study: 29197931

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (thrice weekly sessions of lower-limb aerobic and resistance exercise for 12 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (lower-limb compression therapy)
Number of subjects: 38
Study: 27469583

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (1500 mg twice daily for 24 months)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Cyclophosphamide (2.0 mg/kg per day for 12 months followed by placebo for 12 months)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Cyclophosphamide (control)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 142
Study: 25760509

Group type: EXPERIMENTAL
Intervention: Decortication
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (compression plate only)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 23798345

Group type: EXPERIMENTAL
Intervention: Exposure to diesel exhaust
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exposure to polluted air
Number of subjects: 12
Study: 20496538

Group type: EXPERIMENTAL
Intervention: Combination of medroxyprogesterone 500 mg/d, megestrol acetate 320 mg/d, oral supplementation with eicosapentaenoic acid (EPA), L‐carnitine 4 g/d, thalidomide 200 mg/d
Number of subjects: 332

Group type: COMPARATOR
Intervention: Medroxyprogesterone 500 mg/d or megestrol acetate 320 mg/d
Number of subjects: 332

Group type: COMPARATOR
Intervention: Oral supplementation with eicosapentaenoic acid (EPA)
Number of subjects: 332

Group type: COMPARATOR
Intervention: L‐carnitine 4 g/d
Number of subjects: 332

Group type: COMPARATOR
Intervention: Thalidomide 200 mg/d
Number of subjects: 332
Study: 18468010

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 16176316

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 microg.kg(‐1).min(‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fentanyl 0.025 microg.kg(‐1).min(‐1)
Number of subjects: 22
Study: 12445223

Group type: EXPERIMENTAL
Intervention: MEM+ AB+
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MEM+ AB-
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MEM- AB+
Number of subjects: 25

Group type: COMPARATOR
Intervention: MEM- AB-
Number of subjects: 25
Study: 10622383

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion therapy (40 mg/kg, maximum 2 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 20
Study: 7733027

Group type: EXPERIMENTAL
Intervention: Diet with high polyunsaturated to saturated fat ratio (P:S = 1.0)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Diet with low polyunsaturated to saturated fat ratio (P:S = 0.2)
Number of subjects: 6
Study: 1696669

Group type: EXPERIMENTAL
Intervention: 80 mg of propranolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 mg of brefanolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 mg of brefanolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7025642

Group type: EXPERIMENTAL
Intervention: Auditorally augmented feedback during training exercises (tracing line drawings)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: No auditorally augmented feedback during training exercises (tracing line drawings)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no training exercises)
Number of subjects: 59
Study: 31442599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 31626165

Group type: EXPERIMENTAL
Intervention: Akatinol memantine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Computerized training
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 25925598

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 24027370

Group type: EXPERIMENTAL
Intervention: Pulsatile flow (Group A)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Non-pulsatile flow (Group B)
Number of subjects: 148
Study: 21367954

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 12
Study: 19262961

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Memory Clinics (MMC)
Number of subjects: 220

Group type: COMPARATOR
Intervention: General Practitioners (GP)
Number of subjects: 220
Study: 17419685

Group type: EXPERIMENTAL
Intervention: CEE (conjugated equine oestrogen) 0.6 mg/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: MPA (medroxyprogesterone acetate) 10 mg/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: CEE (conjugated equine oestrogen) 0.6 mg/day and MPA (medroxyprogesterone acetate) 10 mg/day
Number of subjects: 38
Study: 15308069

Group type: EXPERIMENTAL
Intervention: 0.25 U.kg(‐1).d(‐1) of rhGH treatment on 7‐10 PBD, n=16
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0.25 U.kg(‐1).d(‐1) of normal saline as control, n=16
Number of subjects: 32
Study: 11217907

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (1000 microg day(‐1))
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone
Number of subjects: 19
Study: 11069569

Group type: EXPERIMENTAL
Intervention: Ass' milk-based diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Casein hydrolysate milk-based diet
Number of subjects: 21
Study: 9201522

Group type: EXPERIMENTAL
Intervention: dopexamine 2.0 micrograms/kg per min
Number of subjects: 30

Group type: COMPARATOR
Intervention: dopamine 2.5 micrograms/kg per min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: dopexamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: dopamine
Number of subjects: 30
Study: 1434911

Group type: EXPERIMENTAL
Intervention: Ondansetron, 16 mg three times daily for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 14
Study: 2997829

Group type: EXPERIMENTAL
Intervention: Carbamazepine (average dosage 860 mg/day, average duration 29 days)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 25
Study: 29355547

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 5162

Group type: COMPARATOR
Intervention: No β-blockers
Number of subjects: 5162
Study: 26687471

Group type: EXPERIMENTAL
Intervention: L-PRF+ group (n = 17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: L-PRF- group (n = 18)
Number of subjects: 35
Study: 25098313

Group type: EXPERIMENTAL
Intervention: Assessment of Burden of COPD (ABC) tool
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study: 22621795

Group type: EXPERIMENTAL
Intervention: Extended Care (EC)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 201
Study: 20554983

Group type: EXPERIMENTAL
Intervention: NRTI group (coformulated abacavir, zidovudine, and lamivudine)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Protease‐inhibitor group (lopinavir‐ritonavir plus zidovudine‐lamivudine)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Observational group (nevirapine plus zidovudine‐lamivudine)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: NRTI group
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Protease‐inhibitor group
Number of subjects: 560

Group type: COMPARATOR
Intervention: Observational group
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 560
Study: 18612042

Group type: EXPERIMENTAL
Intervention: 15 g of oral carbohydrate (cal) as orange juice
Number of subjects: 19

Group type: COMPARATOR
Intervention: Noncaloric control (nocal)
Number of subjects: 19
Study: 15983800

Group type: COMPARATOR
Intervention: Tiagabine 4 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tiagabine 8 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12358327

Group type: EXPERIMENTAL
Intervention: Two-level noninvasive positive-pressure ventilation (NPPV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo NPPV
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Conventional medical therapy plus two-level NPPV
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional medical therapy plus placebo NPPV
Number of subjects: 20
Study: 10065518

Group type: EXPERIMENTAL
Intervention: Chymopapain (4000 pkat)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Chymopapain (3000 pkat)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (untreated neighboring discs)
Number of subjects: 51
Study: 7726802

Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Integrated treatment (rational emotive therapy, social skills training, exposure in vivo)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 34
Study: 1963383

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Kidney-tonifying decoction (Liu Wei Di Huang or Jin Gui Shen Qi medicinal decoction)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no traditional Chinese decoction)
Number of subjects: 83
Study: 31400103

Group type: EXPERIMENTAL
Intervention: Mobile-based SRH helpline provided by a NGO
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control area (no intervention)
Number of subjects: 405
Study: 29172992

Group type: EXPERIMENTAL
Intervention: Cervarix
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gardasil
Number of subjects: 30
Study: 27284114

Group type: EXPERIMENTAL
Intervention: LixiLan (10 units/5 μg, titrated based on Gla-100 requirement)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Gla-100 (10 units, titrated)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: LixiLan
Number of subjects: 323

Group type: COMPARATOR
Intervention: Gla-100
Number of subjects: 323
Study: 25304364

Group type: EXPERIMENTAL
Intervention: Cycling intervention (moderate-intensity, 20 to 50 minutes per session, 3 times a week)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Attention control (low-intensity stretching)
Number of subjects: 90
Study: 22695488

Group type: EXPERIMENTAL
Intervention: Varenicline for 21 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 17
Study: 19875133

Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study: 18519771

Group type: EXPERIMENTAL
Intervention: dMMR/BRAF(-)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: dMMR
Number of subjects: 533

Group type: COMPARATOR
Intervention: BRAF V600E mutation status
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Combined analysis of dMMR tumors
Number of subjects: 533
Study: 16200539

Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist) at 0.1 mmol/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist) at 0.2 mmol/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gadobenate-dimeglumine (MultiHance) at 0.1 mmol/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gadobenate-dimeglumine (MultiHance) at 0.2 mmol/kg
Number of subjects: 16
Study: 12970204

Group type: EXPERIMENTAL
Intervention: Full arterial revascularization (FAR)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting (CABG)
Number of subjects: 200
Study: 10664331

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation with oral antibiotics (kanamycin and metronidazole three times on the day before surgery)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Mechanical preparation alone (group 1)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation with oral antibiotics (group 2)
Number of subjects: 83
Study: 8858230

Group type: EXPERIMENTAL
Intervention: Nasal insertion of thin video endoscope
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral insertion of thin video endoscope
Number of subjects: 10
Study: 1623912

Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (850 mg) with tolbutamide (500 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (850 mg) with chlorpropamide (250 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Tolbutamide (500 mg) without magnesium hydroxide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chlorpropamide (250 mg) without magnesium hydroxide
Number of subjects: 32
Study: 6147837

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lormetazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30244026

Group type: EXPERIMENTAL
Intervention: Population-based model for estimating breath alcohol concentration (BrAC) from transdermal alcohol concentration (TAC) data.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model-simulated TAC curve and breath analyzer BrAC data comparison.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percent of raw BrAC captured within the eBrAC curve credible bands.
Number of subjects: 0
Study: 29850509

Group type: EXPERIMENTAL
Intervention: Body weight supported treadmill training with visual biofeedback (BB group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Body weight supported treadmill training without visual biofeedback (Control group)
Number of subjects: 30
Study: 27381507

Group type: EXPERIMENTAL
Intervention: Oat biscuits with 4% inulin (OBIN)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oat biscuits (OB)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Glucose solution (reference food)
Number of subjects: 11
Study: 24129610

Group type: EXPERIMENTAL
Intervention: Personalized diet plan with close follow-up by a dietician
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard dietary care via a brochure on healthy eating during pregnancy
Number of subjects: 154
Study: 22972220

Group type: EXPERIMENTAL
Intervention: One session spouse-support enhancement childbirth education
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 61
Study: 19078903

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing after extubation
Number of subjects: 30
Study: 17373639

Group type: EXPERIMENTAL
Intervention: Pump device delivering lispro
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Three daily injections of lispro plus NPH
Number of subjects: 17
Study: 15800765

Group type: EXPERIMENTAL
Intervention: (18)F FDG PET after neoadjuvant treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Complete metabolic remission (detected by PET)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Incomplete metabolic remission (detected by PET)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Histologic regression grade III/IIb
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Histologic regression grade IIa/I
Number of subjects: 32
Study: 11929760

Group type: EXPERIMENTAL
Intervention: E coli-asparaginase
Number of subjects: 700

Group type: COMPARATOR
Intervention: Erwinia-asparaginase
Number of subjects: 700
Study: 9808397

Group type: EXPERIMENTAL
Intervention: Cyriax's concept of the capsular pattern
Number of subjects: 200
Study: 8594004

Group type: EXPERIMENTAL
Intervention: Dehydration trial (DE) with 0.2 liter of fluid leading to dehydration of 4.9 +/- 0.2% body weight
Number of subjects: 7

Group type: COMPARATOR
Intervention: Euhydration trial (EU) with 3.6 +/- 0.4 liter of fluid replacing 95% of fluid losses
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dehydration trial (DE)
Number of subjects: 7
Study: 2775617

Group type: EXPERIMENTAL
Intervention: L-648,051 12.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 778880

Group type: EXPERIMENTAL
Intervention: L-dopa with carbidopa
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Anticholinergic drugs and/or amantadine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study: 31068223

Group type: EXPERIMENTAL
Intervention: Short stretch compression bandaging
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Standard wool and crepe bandaging
Number of subjects: 2600
Study: 28238489

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic removal of endometriosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional laparoscopic removal of endometriosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (robotic and laparoscopic)
Number of subjects: 0
Study: 25426808

Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 389

Group type: COMPARATOR
Intervention: lopinavir/ritonavir
Number of subjects: 389
Study: 23300211

Group type: EXPERIMENTAL
Intervention: Active PAS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham PAS
Number of subjects: 0
Study: 21200079

Group type: EXPERIMENTAL
Intervention: Behavioural activation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 47
Study: 18633001

Group type: EXPERIMENTAL
Intervention: Tele‐VR group (virtual reality therapy at home)
Number of subjects: 10

Group type: COMPARATOR
Intervention: VR group (virtual reality therapy in hospital)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tele‐VR group
Number of subjects: 10
Study: 15928959

Group type: EXPERIMENTAL
Intervention: PRO 160/120
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 12202326

Group type: EXPERIMENTAL
Intervention: Immediate palliative thoracic radiotherapy
Number of subjects: 230

Group type: COMPARATOR
Intervention: Delayed palliative thoracic radiotherapy
Number of subjects: 230
Study: 10333382

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Clonidine with antagonist
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gpp(NH)p
Number of subjects: 11
Study: 8611783

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Hysteroscopic surgery (transcervical resection or laser ablation)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 204
Study: 2007319

Group type: EXPERIMENTAL
Intervention: 300 mg caffeine, t.i.d., administered orally during one of the 8-day periods
Number of subjects: 8

Group type: COMPARATOR
Intervention: 1200 mg anhydrous theophylline administered as a two-stage infusion during 24 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine administration
Number of subjects: 8